Study supports GLP-1 agonists for weight loss
January 10, 2012Research and Development, Sales and Marketing GLP-1, Novo Nordisk, Sanofi, diabetes, lilly
An independent study by academics has concluded that GLP-1 agonist drugs help patients to lose weight – with the effect …
Shire signs strategic partnership deal with ICON
January 10, 2012Research and Development ICON, Shire
Contract research organisation ICON has signed a strategic partnership with Shire Specialty Pharmaceuticals to be the sole global provider of …
BMS to buy hep C firm Inhibitex for $2.5 billion
January 9, 2012Research and Development, Sales and Marketing BMS, Inhibitex, hep C
Bristol-Myers Squibb will acquire virology specialist Inhibitex for $2.5 billion, expanding its infectious disease portfolio. Bristol-Myers Squibb will acquire the …
AstraZeneca leaks confidential information
January 9, 2012Sales and Marketing AstraZeneca, data leak
There have been red faces at AstraZeneca after the company sent confidential information to analysts by mistake. It was forced …
Novartis recalls products as GMP issues close OTC facility
January 9, 2012Manufacturing and Production FDA, Novartis, OTC
Novartis has revealed that it is temporarily shutting down a manufacturing facility in Nebraska, US, and recalling four products as …
J&J to pay $1 billion for Risperdal charges
January 9, 2012Sales and Marketing J&J, JJ, Janssen, Risperdal
Johnson & Johnson will pay more than $1 billion in the US to resolve a civil investigation into the marketing …
Celgene appoints Dr David Gillen as its UK and Ireland medical director
January 9, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Celgene
Celgene has appointed former Pfizer man Dr David Gillen as its new UK and Ireland medical director. Gillen brings much …
Hospira faces lawsuits from disgruntled investors
January 9, 2012Manufacturing and Production Hospira, generics, manufacturing
Angry investors in US generic drugmaker Hospira have filed a class action lawsuit against the company, alleging that it misled …
Merck chief defends ‘bumpy’ 2011
January 6, 2012Sales and Marketing Kenneth Frazier, Merck
Kenneth Frazier has defended his company’s ‘bumpy’ performance in 2011, and has highlighted key drugs for investors to watch. Frazier …
2011 Year In Review
January 6, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Europe, emerging markets, year in review
A round up of some of the key themes in pharma’s yearEUROPE IN CRISIS While the Eurozone has averted meltdown …
New requirements for the technical validations of Marketing Authorisation Applications
January 6, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
The current EU- eCTD v3.1 validation criteria came into force on 1st September 2011 for the technical validation for all …
GSK faces fine over Argentina clinical trial
January 6, 2012Research and Development, Sales and Marketing Argentina, GSK, Vaccine, deaths, emerging markets
A court in Argentina says GSK should be fined for irregularities in recruitment during a trial in which children died. …
FDA: don’t broadcast discussion on off-label uses
January 6, 2012Medical Communications FDA, Facebook, Twitter, off label, social media
The FDA has released long-awaited guidance for pharma firms about social media use. The FDA held a two-day public hearing …
Lilly pessimistic on 2012 performance
January 6, 2012Sales and Marketing Eli Lilly, lilly, zyprexa
Lilly is forecasting a drop in revenue and profits for 2012, as it prepares for life without its blockbuster antipsychotic …
Keep prescribing Lipitor – the generics are nearly here, says Pfizer
January 5, 2012Medical Communications, Sales and Marketing Lipitor, NHS, Pfizer, statin prescribing
Pfizer has launched a campaign to persuade UK doctors to keep prescribing Lipitor ahead of its patent expiry in May. …
Biogen inks $299m deal for rare genetic disorder drug
January 5, 2012Research and Development, Sales and Marketing Biogen, Isis Pharma
Biogen has signed a new deal with drug discovery firm Isis for its spinal muscular atrophy drug ISIS-SMNRx. Biogen will pay …
AstraZeneca to take Alzheimer’s drug into phase II
January 5, 2012Research and Development Alzheimer's, AstraZeneca, Targacept
AstraZeneca is to continue the development of Targacept’s AZD1446 as a treatment for Alzheimer’s disease.AZD1446 is a selective modulator of …
UK to expand telehealth to three million people
January 4, 2012Medical Communications, Sales and Marketing NHS, long term conditions, telecare, telehealth
The NHS is to expand the use of telehealth, allowing doctors to remotely monitor patients with long-term conditions.The government’s Care …
Orphan status for haemophilia gene therapy
January 4, 2012Research and Development AMT, gene therapy, haemophilia
Amsterdam Molecular Therapeutics has been granted an orphan drug designation for its gene therapy for haemophilia B.The FDA’s orphan designation …
Missing trial data ‘threatens integrity of medicine’
January 4, 2012Research and Development, Sales and Marketing BMJ, clincial trial data, disclosure
Missing clinical trial data can harm patients and lead to needless costs for health systems, according to new research. A …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
